

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline *BRCA1/2*-Mutated Ovarian Carcinoma or Other Solid Tumors



Rebecca Kristeleit¹, Geoffrey I. Shapiro², Howard A. Burris³, Amit M. Oza⁴, Patricia LoRusso⁵, Manish R. Patel⁶, Susan M. Domchek⁷, Judith Balmaña⁸, Yvette Drew⁹, Lee-may Chen¹⁰, Tamar Safra^{11,12}, Ana Montes¹³, Heidi Giordano¹⁴, Lara Maloney¹⁴, Sandra Goble¹⁵, Jeff Isaacson¹⁶, Jim Xiao¹⁷, Jen Borrow¹⁸, Lindsey Rolfe¹⁹, and Ronnie Shapira-Frommer²⁰

Abstract

Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I–II study was the first to evaluate single-agent oral rucaparib at multiple doses.

Experimental Design: Part 1 (phase I) sought to determine the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors. Part 2A (phase II) enrolled patients with platinum-sensitive, high-grade ovarian carcinoma (HGOC) associated with a germline *BRCA1/2* mutation who received two to four prior regimens and had a progression-free interval of 6 months or more following their most recent platinum therapy. The primary endpoint was investigator-assessed objective response rate (ORR) by RECIST version 1.1.

Results: In part 1, 56 patients received oral rucaparib (40 to 500 mg once daily and 240 to 840 mg twice daily). No MTD

was identified per protocol-defined criteria; 600 mg twice daily was selected as the RP2D based on manageable toxicity and clinical activity. Pharmacokinetics were approximately dose-proportional across all dose levels. In part 2A, 42 patients with germline *BRCA1/2*-mutated HGOC received rucaparib 600 mg twice daily. Investigator-assessed ORR was 59.5%. The most common treatment-emergent adverse events (all grades) were asthenia/fatigue (85.7%; 36/42), nausea (83.3%; 35/42), anemia (71.4%; 30/42), alanine transaminase and/or aspartate transaminase elevations (57.1%; 24/42), and vomiting (54.8%; 23/42). Among 98 patients, 5 (5.1%) discontinued because of an adverse event (excluding disease progression).

Conclusions: Rucaparib was tolerable and had activity in patients with platinum-sensitive germline *BRCA1/2*-mutated HGOC. *Clin Cancer Res*; 23(15); 4095–106. ©2017 AACR.

Introduction

PARP enzymes make up a 17-member superfamily of nuclear enzymes; PARP-1, -2, and -3 are activated by and promote the repair of DNA damage (1). PARP-1 and -2 are the most abundant enzymes and have a major role in the repair of DNA single-strand

breaks through the base excision repair/single-strand break repair pathway (1). PARP inhibition results in accumulation of unrepaired single-strand breaks, which result in collapsed replication forks and an accumulation of DNA double-strand breaks (2, 3). These double-strand breaks are repaired by the homologous

¹Research Department of Oncology, UCL Cancer Institute, London, United Kingdom. ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ³Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, Tennessee. ⁴Department of Obstetrics and Gynecology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. ⁵Department of Medical Oncology, Yale University, New Haven, Connecticut. ⁶Department of Medical Oncology, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida. ⁷Department of Medical Oncology, Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania. ⁸Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. ⁹Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom. ¹⁰Department of Obstetrics, Gynecology, and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. ¹¹Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. ¹²Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ¹³Department of Medical Oncology, Guy's Hospital, London, United Kingdom. ¹⁴Clinical Science,

Clovis Oncology, Inc., Boulder, Colorado. ¹⁵Biostatistics, Clovis Oncology, Inc., Boulder, Colorado. ¹⁶Statistics and Data Management, Clovis Oncology, Inc., Boulder, Colorado. ¹⁷Clinical Pharmacology and Nonclinical DMPK, Clovis Oncology, Inc., Boulder, Colorado. ¹⁸Clinical Development, Clovis Oncology, Inc., Boulder, Colorado. ¹⁹Clinical and Preclinical Development, Clovis Oncology, Inc., Boulder, Colorado. ²⁰Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Clinical Trial registration ID: NCT01482715.

Corresponding Author: Rebecca Kristeleit, UCL Cancer Institute, 72 Huntley Street, London WC1E 6BT, United Kingdom. Phone: 4420-7679-0744; Fax: 4420-3447-9055; E-mail: r.kristeleit@ucl.ac.uk

doi: 10.1158/1078-0432.CCR-16-2796

©2017 American Association for Cancer Research.

Translational Relevance

PARP-1, PARP-2, and PARP-3 enzymes are key mediators of DNA repair in response to single-strand breaks. Inhibition of these enzymes results in accumulation of double-strand DNA breaks that are repaired through BRCA1- and BRCA2-mediated homologous recombination (HR). Defects in HR repair (e.g., *BRCA1* and *BRCA2* mutations) can sensitize tumors to PARP inhibition through synthetic lethality. This phase I–II study was the first to fully evaluate single-agent oral rucaparib, a PARP inhibitor, in heavily pretreated patients with advanced solid tumors. In part 1, pharmacokinetics were dose proportional, safety was manageable, and rucaparib 600 mg twice daily was the recommended phase II dose. In part 2A, rucaparib 600 mg twice-daily treatment had robust antitumor activity in patients with platinum-sensitive ovarian cancer and a germline *BRCA1/2* mutation. These results support further clinical and translational investigation of rucaparib in tumors with HR repair deficiency, potentially extending applicability beyond *BRCA*-mutated cancers.

recombination (HR) repair pathway, in which *BRCA1* and *BRCA2* are key proteins (4–6). It is widely accepted that tumors with a *BRCA1/2* mutation or other HR deficiency (HRD) are selectively sensitive to PARP inhibition by a mechanism of synthetic lethality (7–9). Several recent reports have proposed additional models by which PARP inhibition may result in synthetic lethality (10, 11). For example, PARP inhibition may affect the role these enzymes play in the alternative nonhomologous end-joining DNA repair pathway, which is upregulated in HR-deficient cells (12, 13). In addition, PARP inhibitors have been shown to trap PARP-1 and -2 at the site of the DNA break (14). These trapped PARP–DNA complexes may directly damage the cell by obstructing replication forks, requiring HR repair for resolution (10, 14).

Several PARP inhibitors are currently in development for the treatment of patients with tumors harboring HRD, including those with a *BRCA1/2* mutation (15–26). Single-agent olaparib is approved in the United States for the treatment of patients with advanced germline *BRCA1/2*-mutated ovarian cancer who have received three or more lines of chemotherapy (27, 28). Rucaparib (CO-338; formerly known as AG-014447 and PF-01367338) is a potent small-molecule inhibitor of PARP-1, -2, and -3 (29, 30), and was approved in the United States in December 2016 for the treatment of patients with advanced ovarian cancer associated with deleterious germline or somatic *BRCA* mutations who have received two or more chemotherapies (31). Consistent with the concept of synthetic lethality, rucaparib is preferentially cytotoxic to cells with a *BRCA1* or *BRCA2* mutation or epigenetically silenced *BRCA1* (7, 32).

An open-label, phase II study investigated intermittent dosing of intravenous rucaparib (5 days of a 21-day cycle), as well as intermittent and continuous dosing of oral rucaparib (7, 14, or 21 days of a 21-day cycle) in small cohorts of patients with advanced ovarian or breast cancer associated with a germline *BRCA1/2* mutation (33). This study provided evidence that continuous dosing of oral rucaparib led to a higher rate of response than intermittent intravenous dosing (response rate, 18% vs. 2%). The intravenous formulation was discontinued. However, the maximum oral dose of rucaparib 600 mg twice daily for 21 continuous

days was evaluated in only 1 patient, and the study did not establish a recommended phase II dose (RP2D) for the oral formulation, which was a secondary endpoint.

The phase I–II study reported here was the first to fully evaluate single-agent oral rucaparib administered for multiple cycles in patients with an advanced solid tumor, including a cohort of patients with *BRCA1/2*-mutated ovarian cancer who had received multiple prior treatments. The objectives of this study included characterization of the safety and pharmacokinetic profiles, assessment of preliminary clinical activity, and establishment of the RP2D of rucaparib. Here, we present results from Study 10 part 1 (phase I dose escalation), as well as part 2A (phase II expansion) that evaluated the RP2D of rucaparib as single-agent treatment in patients with platinum-sensitive, high-grade ovarian cancer (HGOC) associated with a germline *BRCA1/2* mutation.

Materials and Methods

Study design and patients

This is an ongoing, three-part, open-label, phase I–II study of single-agent oral rucaparib (ClinicalTrials.gov identifier, NCT01482715). It was approved by the institutional review board at each study site and is being conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation. Patients provided written consent before participating in the study. Part 1 (phase I dose escalation) enrolled patients who were at least 18 years of age with an advanced solid tumor that had progressed on standard treatment. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1 and adequate hematologic, hepatic, and renal function. Measurable disease and a known *BRCA1/2* mutation were not required. The primary objectives of part 1 were to characterize the safety and pharmacokinetic profile of oral rucaparib administered as a continuous daily dose and establish the MTD and RP2D in patients with an advanced solid tumor. Antitumor activity was evaluated as a secondary objective.

Part 2A (phase II expansion) evaluated the RP2D of oral rucaparib in patients with platinum-sensitive, relapsed, high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer associated with a germline *BRCA1/2* mutation. Eligible patients received between two and four prior treatment regimens, had an ECOG PS of 0 to 1, had a progression-free interval (PFI) of 6 months or longer after their most recent platinum-based regimen, and had measurable disease (of any size; with or without visceral metastasis) per RECIST version 1.1. Part 2A utilized a Simon two-stage design requiring two or more responses in the first 21 patients to continue to stage 2; total planned enrollment was 41 patients. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST. Secondary objectives included evaluation of duration of response and safety. An independent radiology review of ORR for patients in part 2A was performed retrospectively.

Study treatment

Using a standard 3 + 3 design for dose escalation (part 1), patients received oral rucaparib once daily or twice daily in 21-day continuous treatment cycles, starting at 40 mg once daily with escalations to 80, 160, 300, and 500 mg once daily, then further escalation to 240, 360, 480, 600, and 840 mg twice daily. The protocol was amended approximately 10 months after

enrollment began to allow inpatient dose escalation. Patients in part 2A received the RP2D of oral rucaparib established in part 1. Treatment continued until disease progression or unacceptable toxicity. A new cycle of treatment could begin if a patient's absolute neutrophil count was $1.0 \times 10^9/L$ or greater, platelet count was $75.0 \times 10^9/L$ or greater, and nonhematologic toxicities had returned to baseline or were grade 1 or less.

Definition of dose-limiting toxicity and MTD

In part 1, dose-limiting toxicities (DLT) were defined as any of the following events that occurred during cycle 1 and were assessed by the investigator as related to rucaparib: absolute neutrophil count less than $0.5 \times 10^9/L$ lasting for more than 5 days or febrile neutropenia; platelets less than $25 \times 10^9/L$ or platelets less than $50 \times 10^9/L$ with bleeding requiring a platelet transfusion; grade 4 anemia; or any nonhematologic adverse event (AE) grade 3 or greater (except nausea, vomiting, and diarrhea, if well controlled by systemic medication, and alopecia). Dose escalation continued until 33% or more of patients treated at a dose level experienced a DLT. The next lower dose was then considered the MTD.

Pharmacokinetics, safety, and efficacy assessments

Pharmacokinetic assessments in part 1 included single-dose and steady-state (day 15) profiles in cycle 1 and trough levels in selected cycles. Blood was collected prior to rucaparib dosing and from 15 minutes to 24 hours after dosing on days 1 and 15. Samples for pharmacokinetic analysis were collected before and/or after the morning dose for all patients on a twice-daily dosing schedule. Safety assessments included evaluation of AEs, hematology, clinical chemistry, vital signs, body weight, concomitant medications and/or procedures, ECOG PS, electrocardiograms, and rucaparib dose modifications. Adverse events were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (34).

Tumor assessments consisted of clinical examination and computed tomography scans of the chest, abdomen, and pelvis (with appropriate slice thickness per RECIST; ref. 35). Other assessments (e.g., MRI) were performed only if clinically required. Tumor assessments were performed at screening, prior to cycles 3, 5, and 7, and every three cycles of treatment thereafter from cycle 10. Tumor responses (per RECIST) were assessed in all patients; however, for those without measurable disease at baseline (permitted in part 1), only a best response of stable or progressive disease could be achieved. Response in patients with ovarian cancer was also assessed using Gynecologic Cancer InterGroup (GCIg) cancer antigen 125 (CA-125) criteria (36). Confirmatory scans were required 4 to 6 weeks after an initial complete response (CR) or partial response (PR) was noted.

Dose reductions

Up to three dose reduction steps were permitted to manage treatment-related toxicity. In the event of grade 3 or 4 toxicity, treatment was held until resolution to grade 2 or less before readministration of rucaparib. If dosing was interrupted for more than 14 consecutive days because of toxicity, treatment was discontinued unless the patient was deriving clinical benefit and the sponsor approved continuation of treatment. In part 1, rucaparib was reduced to the next lower dose level. In part 2A, rucaparib dose was reduced by increments of 120 mg.

Statistical analysis

For part 1, it was estimated that 6 to 12 dose-escalation cohorts, with a minimum of 3 patients each, would be needed to evaluate the RP2D of oral rucaparib. In part 2A, it was estimated that at least 41 patients evaluable for response would be needed to evaluate the efficacy of rucaparib.

The single-dose and steady-state rucaparib pharmacokinetic data following oral administration were analyzed using noncompartmental methods. The pharmacokinetic parameters included area under the concentration time curve (AUC) from time 0 to last measurable concentration, maximum concentration (C_{max}), time to C_{max} (T_{max}), half-life ($t_{1/2}$), apparent steady-state clearance (CL_{ss}/F), and accumulation ratio. Time to reach steady state was estimated on the basis of the plasma trough concentration-time profile. Dose proportionality was assessed for once-daily and twice-daily dosing using log-transformed pharmacokinetic parameters and dose by linear regression. The effect of food on single-dose rucaparib exposure, as measured by C_{max} and AUC time 0 to 24 hours (AUC_{0-24}), was assessed at the 40 and 300 mg once-daily dose levels.

Safety analyses were performed by study part and by dose level in all patients who received at least one dose of rucaparib. The ORR was summarized for all patients enrolled in part 2A who received at least one dose of rucaparib, and presented as percentage with 95% confidence interval (CI) using Clopper-Pearson methodology. Duration of confirmed response (CR or PR) was measured from the date of first response until the date that progressive disease was objectively documented, or censored at the last tumor evaluation. Kaplan-Meier methodology was used to analyze duration of response and presented with the median and 95% CI values.

Results

Part 1 (phase I dose escalation)

Patients and treatments. Between December 2011 and October 2013, 56 patients were enrolled into part 1 of the study. Results from part 1 are based on a visit cut-off date of November 30, 2015.

Baseline characteristics are presented in Table 1. Most patients had either breast (48.2%; 27/56) or ovarian (35.7%; 20/56) cancer. The majority of patients (64.3%; 36/56) had a germline *BRCA1* or *BRCA2* mutation identified by local testing; for 7 of 56 patients (12.5%), germline status was not confirmed as local *BRCA* testing was conducted using DNA extracted from tissues other than blood or buccal samples (e.g., tumor tissue only). For 20 of 56 patients (35.7%), a *BRCA* mutation was not detected or no test was performed.

Twenty-six patients received rucaparib once daily, at dose levels of 40 mg ($n = 6$), 80 mg ($n = 3$), 160 mg ($n = 4$), 300 mg ($n = 9$), and 500 mg once daily ($n = 4$); 30 patients received rucaparib twice daily, at dose levels of 240 mg ($n = 3$), 360 mg ($n = 8$), 480 mg ($n = 9$), 600 mg ($n = 7$), and 840 mg twice daily ($n = 3$). Median treatment exposure across all dose levels was 3.2 months (range, 0.0–37.9); 20 of 56 patients (35.7%) received treatment for 6 months or more. One of 8 patients treated with rucaparib 360 mg twice daily experienced a DLT of grade 3 nausea not well controlled by systemic medication; no DLTs were observed at any other dose level. No MTD was identified as per the protocol-specified criteria.

Safety. Across dose levels, treatment-emergent AEs were mostly grade 1 or 2 in severity. No grade 4 events were reported

Kristeleit et al.

Table 1. Baseline patient and disease characteristics

Parameter	Part 1 phase I (n = 56)	Part 2A phase II (n = 42)
Age, median (range), y	51 (21-71)	57 (42-84)
Gender, n (%)		
Female	51 (91.1)	42 (100.0)
Male	5 (8.9)	0 (0)
ECOG PS, n (%)		
0	29 (51.8)	26 (61.9)
1	27 (48.2)	16 (38.1)
Germline <i>BRCA1/2</i> mutation, n (%)		
Yes	36 (64.3)	42 (100.0)
No mutation detected	9 (16.1)	0 (0)
No test performed ^a	11 (19.6)	0 (0)
<i>BRCA</i> gene mutation, n (%)		
<i>BRCA1</i>	22 (39.3)	30 (71.4)
<i>BRCA2</i>	14 (25.0)	12 (28.6)
Type of cancer, n (%)		
Breast	27 (48.2)	0 (0)
Ovarian	20 (35.7)	42 (100.0)
Pancreatic (exocrine)	2 (3.6)	0 (0)
Other ^b	7 (12.5)	0 (0)
Histologic classification, n (%)		
Serous	NA	37 (88.1)
Mixed	NA	3 (7.1)
Endometrioid	NA	1 (2.4)
Clear cell	NA	1 (2.4)
Platinum status of patients with ovarian cancer, n (%) ^c		
Refractory	1 (1.8)	0 (0)
Resistant	11 (19.6)	0 (0)
Sensitive	8 (14.3)	42 (100.0)
Progression-free interval from last platinum therapy, n (%)		
≥6-12 mo	NA	32 (76.2)
>12 mo	NA	10 (23.8)
Previous anticancer therapies, median (range)	4 (1-15)	2 (2-4)
≥3 previous anticancer therapies, n (%)	41 (73.2)	15 (35.7)
Previous chemotherapies, median (range)	3 (1-13)	2 (2-4)
≥3 previous chemotherapies, n (%)	37 (66.1)	15 (35.7)
Previous platinum-based chemotherapies, median (range)	1 (0-5)	2 (2-4)
≥3 previous platinum-based chemotherapies, n (%)	9 (16.1)	13 (31.0)

Abbreviation: NA, not applicable.

^aPatients did not have local or central *BRCA* testing performed.^bOne each of the following: small-cell lung cancer, gastric cancer, colon cancer, desmoplastic round cell tumor, mesenchymal chondrosarcoma of the skull, astrocytoma, and angiosarcoma.^cPlatinum status was not applicable for 36 patients (64.3%) in part 1.

(Table 2). The most common (≥20% of patients) treatment-emergent AEs were asthenia/fatigue, gastrointestinal disorders (nausea, vomiting, and diarrhea), myelosuppression (anemia, thrombocytopenia, and neutropenia), decreased appetite, and elevated alanine transaminase (ALT) and/or aspartate transaminase (AST) levels. Treatment-emergent AEs of elevations in blood creatinine and ALT/AST levels were reported in 8.9% (5/56) and 25.0% (14/56) of patients and were mostly grade 1 or 2. Anemia was the most common grade 3 treatment-emergent AE, reported in 5 of 56 patients (8.9%) across all doses, with the highest incidence reported with the rucaparib 600 mg twice-daily dose (28.6%; 2/7). Across all cohorts, 11 of 56 patients (19.6%) had a dose reduction because of a treatment-emergent AE. At the visit cut-off date (November 30, 2015), 2 of 56 patients (3.6%) continued to receive treatment, 50 of 56 patients (89.3%) had discontinued because of disease progression (71.4%) or clinical deterioration (17.9%), and 1 patient each (1.8%) discontinued for the following reasons: vaginal fistula (considered related to disease progression), increase in CA-125 level, physician's decision, or eligibility violation (QTc higher than the allowed maximum of 450 ms). No treatment-related deaths were

reported; 3 deaths resulting from disease progression were reported during the study.

Efficacy. In this portion of the study, objective responses or prolonged stable disease (SD) occurred in patients with a germline *BRCA* mutation. There were 2 patients who achieved a confirmed CR in part 1 (Table 3). One patient with platinum-sensitive ovarian cancer and a germline *BRCA1* mutation receiving rucaparib 300 mg once daily had a PR at 6 weeks (first on-study assessment) and eventually achieved a CR at 54 weeks. At the visit cut-off date, the patient had been on study for 165 weeks, with a confirmed CR for 111 weeks. A patient with breast cancer and a germline *BRCA1* mutation receiving rucaparib 360 mg twice daily had a PR at 6 weeks (first on-study assessment) and achieved a CR at 18 weeks, which lasted for 60 weeks.

A confirmed PR was achieved in 6 patients (Table 3). One patient with breast cancer and a germline *BRCA1* mutation receiving rucaparib 300 mg once daily had a PR for 15 weeks. One patient with pancreatic cancer and a germline *BRCA2* mutation receiving rucaparib 360 mg twice daily had a PR for 28 weeks. In the rucaparib 480 mg twice-daily cohort, 1 patient with breast

Table 2. Treatment-emergent AEs (occurring in $\geq 20\%$ of patients in part 1 or part 2A) by rucaparib dose

Adverse event	Part 1 (phase I dose escalation), n (%)							Part 2A (phase II expansion), n (%)				
	40-500 mg QD (n = 26) ^a	240 mg BID (n = 3)	360 mg BID (n = 8)	480 mg BID (n = 9)	600 mg BID (n = 7)	840 mg BID (n = 3)	All doses (n = 56)	600 mg BID (n = 42)				All grade
	All grade	All grade	All grade	All grade	All grade	All grade	All grade	Grade 1	Grade 2	Grade 3	Grade 4	
Any adverse event	26 (100.0)	3 (100.0)	8 (100.0)	8 (88.9)	7 (100.0)	3 (100.0)	55 (98.2)	0 (0)	7 (16.7)	26 (61.9)	6 (14.3)	42 (100.0)
Asthenia/fatigue	10 (38.5)	2 (66.7)	5 (62.5)	5 (55.6)	5 (71.4)	1 (33.3)	28 (50.0)	8 (19.0)	17 (40.5)	11 (26.2)	0 (0)	36 (85.7)
Nausea	12 (46.2)	0 (0)	6 (75.0)	4 (44.4)	4 (57.1)	3 (100.0)	29 (51.8)	17 (40.5)	15 (35.7)	3 (7.1)	0 (0)	35 (83.3)
Anemia ^b	5 (19.2)	0 (0)	4 (50.0)	3 (33.3)	4 (57.1)	1 (33.3)	17 (30.4)	7 (16.7)	7 (16.7)	13 (31.0)	3 (7.1)	30 (71.4)
AST/ALT increased	2 (7.7)	0 (0)	2 (25.0)	3 (33.3)	6 (85.7)	1 (33.3)	14 (25.0)	11 (26.2)	7 (16.7)	6 (14.3)	0 (0)	24 (57.1)
Vomiting	10 (38.5)	0 (0)	3 (37.5)	5 (55.6)	4 (57.1)	2 (66.7)	24 (42.9)	12 (28.6)	8 (19.0)	3 (7.1)	0 (0)	23 (54.8)
Constipation	8 (30.8)	0 (0)	2 (25.0)	2 (22.2)	1 (14.3)	0 (0)	13 (23.2)	15 (35.7)	7 (16.7)	0 (0)	0 (0)	22 (52.4)
Headache	5 (19.2)	0 (0)	2 (25.0)	1 (11.1)	2 (28.6)	1 (33.3)	11 (19.6)	13 (31.0)	5 (11.9)	1 (2.4)	0 (0)	19 (45.2)
Abdominal pain	7 (26.9)	0 (0)	2 (25.0)	3 (33.3)	1 (14.3)	1 (33.3)	14 (25.0)	8 (19.0)	7 (16.7)	3 (7.1)	0 (0)	18 (42.9)
Dysgeusia	1 (3.8)	1 (33.3)	2 (25.0)	1 (11.1)	1 (14.3)	2 (66.7)	8 (14.3)	11 (26.2)	6 (14.3)	0 (0)	0 (0)	17 (40.5)
Diarrhea	4 (15.4)	1 (33.3)	1 (12.5)	2 (22.2)	2 (28.6)	3 (100.0)	13 (23.2)	8 (19.0)	8 (19.0)	0 (0)	0 (0)	16 (38.1)
Thrombocytopenia ^c	0 (0)	0 (0)	1 (12.5)	2 (22.2)	5 (71.4)	0 (0)	8 (14.3)	8 (19.0)	6 (14.3)	1 (2.4)	0 (0)	15 (35.7)
Blood creatinine increased	2 (7.7)	1 (33.3)	0 (0)	1 (11.1)	1 (14.3)	0 (0)	5 (8.9)	9 (21.4)	5 (11.9)	0 (0)	0 (0)	14 (33.3)
Neutropenia ^d	3 (11.5)	0 (0)	1 (12.5)	3 (33.3)	3 (42.9)	0 (0)	10 (17.9)	4 (9.5)	2 (4.8)	4 (9.5)	3 (7.1)	13 (31.0)
Decreased appetite	9 (34.6)	2 (66.7)	3 (37.5)	1 (11.1)	0 (0)	1 (33.3)	16 (28.6)	6 (14.3)	5 (11.9)	1 (2.4)	0 (0)	12 (28.6)
Abdominal distension	3 (11.5)	0 (0)	2 (25.0)	2 (22.2)	1 (14.3)	0 (0)	8 (14.3)	6 (14.3)	4 (9.5)	0 (0)	0 (0)	10 (23.8)
Blood alkaline phosphatase increased	2 (7.7)	0 (0)	0 (0)	2 (22.2)	4 (57.1)	0 (0)	8 (14.3)	10 (23.8)	0 (0)	0 (0)	0 (0)	10 (23.8)
Dyspnea	2 (7.7)	0 (0)	3 (37.5)	3 (33.3)	1 (14.3)	1 (33.3)	10 (17.9)	8 (19.0)	1 (2.4)	1 (2.4)	0 (0)	10 (23.8)
Upper respiratory tract infection	1 (3.8)	0 (0)	1 (12.5)	0 (0)	0 (0)	0 (0)	2 (3.6)	6 (14.3)	4 (9.5)	0 (0)	0 (0)	10 (23.8)
Cough	3 (11.5)	1 (33.3)	0 (0)	3 (33.3)	2 (28.6)	2 (66.7)	11 (19.6)	7 (16.7)	1 (2.4)	1 (2.4)	0 (0)	9 (21.4)
Dizziness	2 (7.7)	1 (33.3)	2 (25.0)	2 (22.2)	2 (28.6)	0 (0)	9 (16.1)	7 (16.7)	1 (2.4)	1 (2.4)	0 (0)	9 (21.4)

NOTE: Table is sorted by decreasing incidence in part 2A patients.

Abbreviations: BID, twice daily; QD, once daily.

^a40 mg QD (n = 6), 80 mg QD (n = 3), 160 mg QD (n = 4), 300 mg QD (n = 9), and 500 mg QD (n = 4).^bAnemia and/or low/decreased hemoglobin.^cThrombocytopenia and/or low or decreased platelets.^dNeutropenia and/or low or decreased absolute neutrophil count.

cancer and a germline *BRCA2* mutation, 1 patient with platinum-resistant ovarian cancer and a germline *BRCA2* mutation, and 1 patient with breast cancer and a tumor *BRCA1* mutation achieved a PR of 116, 37, and 21 weeks' duration, respectively. One patient with platinum-resistant ovarian cancer and a tumor *BRCA1* mutation who received rucaparib 600 mg twice daily had a PR for 13 weeks. Twenty-two patients (15 with ovarian, 6 with breast, and 1 with colon cancer) had a best response of SD; 14 patients had durable SD for more than 24 weeks. Of 13 patients with ovarian cancer associated with a *BRCA* mutation who received rucaparib twice daily (360–840 mg), 2 (15.4%; 95% CI, 1.9–45.4) achieved a confirmed PR, 10 (76.9%) had a best response of SD, and 1 (7.7%) was not evaluable. The best response in target lesions for all phase I patients with measurable disease is presented in Fig. 1A.

Pharmacokinetics. Fifty-six patients entered the dose-escalation portion of the study and received oral rucaparib with or without food at doses ranging from 40 to 500 mg once daily and 240 to 840 mg twice daily (480–1,680 mg/day). Pharmacokinetic parameters are summarized in Table 4. The mean plasma rucaparib concentration–time profiles by dose level on cycle 1 days 1 and 15 following once-daily and twice-daily dosing are presented in Supplementary Figs. S1 and S2, and the relationship between dose level and exposure is presented in Supplementary Fig. S3. Plasma exposure of rucaparib was approximately dose proportional. The median values of T_{max} ranged from 1.5 to 6 hours

across all doses, suggesting relatively fast absorption. The estimated $t_{1/2}$ for once-daily dosing was approximately 17 hours. Steady state appeared to be achieved by day 8 with once-daily or twice-daily dosing based on the predose plasma concentration of rucaparib. The estimated mean values of CL_{SS}/F ranged from 26.7 to 47.5 L/hour for once-daily dosing and from 26.2 to 58.6 L/hour for twice-daily dosing. The accumulation ratio of rucaparib plasma exposure at steady state ranged from 1.06 to 1.8 for C_{max} and 1.6 to 2.3 for AUC_{0-24} with once-daily dosing, and from 2.6 to 4.9 for C_{max} and 1.47 to 5.44 for AUC_{0-12} with twice-daily dosing. The accumulation on a twice-daily schedule was approximately twice that of the once-daily schedule. The time to steady state and the observed accumulation ratios are consistent with the $t_{1/2}$ values, suggesting lack of time-dependent pharmacokinetics. The effect of a high-fat meal on rucaparib pharmacokinetics was evaluated in 3 patients at 40 mg once daily and 6 patients at 300 mg once daily. A high-fat meal did not cause clinically meaningful changes of rucaparib pharmacokinetics at these dose levels (Supplementary Table S1).

RP2D. On the basis of protocol-specified criteria, no MTD was identified for dose levels of 40 mg once daily up to 840 mg twice daily in part 1. The 600 mg twice-daily dose was selected as the RP2D upon consideration of the manageable safety and antitumor activity of rucaparib, as well as the pharmacokinetic profile observed in patients in part 1. No patients in the 600 mg twice-daily cohort discontinued because of an AE; however,

Kristeleit et al.

Table 3. Antitumor activity in patients with advanced tumors who received rucaparib in part 1 and investigator-assessed response in patients with germline *BRCA1/2*-mutated ovarian cancer from part 2A

Part 1 (phase I dose escalation) patients with advanced solid tumors (n = 56)					
Dose received	Confirmed CR or PR (RECIST)	Duration of response (wk)	Type of cancer	BRCA Mutation	Platinum status
300 mg QD	CR	111	Ovarian	Germline <i>BRCA1</i>	Sensitive
300 mg QD	PR	15	Breast	Germline <i>BRCA1</i>	NA
360 mg BID	CR	60	Breast	Germline <i>BRCA1</i>	NA
360 mg BID	PR	28	Pancreatic	Germline <i>BRCA2</i>	NA
480 mg BID	PR	116	Breast	Germline <i>BRCA2</i>	NA
480 mg BID	PR	37	Ovarian	Germline <i>BRCA2</i>	Resistant
480 mg BID	PR	21	Breast	Tumor <i>BRCA1</i>	NA
600 mg BID	PR	13	Ovarian	Tumor <i>BRCA1</i>	Resistant

Part 2A (phase II expansion) patients with germline <i>BRCA1/2</i> -mutated ovarian cancer (n = 42)	
RECIST best confirmed response, n [% (95% CI)]	
CR	4 (9.5)
PR	21 (50.0)
SD	12 (28.6)
PD	2 (4.8)
NE	3 (7.1)
RECIST ORR, n [% (95% CI)]	25 [59.5 (43.3–74.4)]
RECIST/CA-125 ORR, n [% (95% CI)]	35 [83.3 (68.6–93.0)]
RECIST ORR by part 2A patient subsets, n/N [% (95% CI)]	
BRCA gene mutation	
BRCA1	19/30 [63.3 (43.9–80.1)]
BRCA2	6/12 [50.0 (21.1–78.9)]
PFI	
6–12 mo	17/32 [53.1 (34.7–70.9)]
>12 mo	8/10 [80.0 (44.4–97.5)]
≥3 prior chemotherapy regimens	9/15 [60.0 (32.3–83.7)]
Duration of response, median (95% CI), mo	7.8 (5.6–10.5)

Abbreviations: BID, twice daily; NA, not available; NE, not evaluable; PD, progressive disease; QD, once daily.

myelosuppression requiring dose modification was observed in some patients after several cycles of treatment. Furthermore, antitumor activity was observed in patients in this cohort.

Part 2A (phase II expansion)

Patients and treatments. Part 2A of the study evaluated oral rucaparib in patients with platinum-sensitive, high-grade serous, endometrioid, mixed histology, or clear cell ovarian cancer associated with a germline *BRCA1/2* mutation. The majority of patients had high-grade serous cancer (Table 1). In stage 1, 3 of the first 5 patients enrolled achieved a RECIST response, satisfying the criteria to continue to stage 2. A total of 42 patients were enrolled into part 2A; the majority of patients (71.4%; 30/42) had a *BRCA1* mutation, and 28.6% (12/42) had a *BRCA2* mutation (Table 1). The median number of prior chemotherapy regimens was two (range, 2–4); 15 of 42 patients (35.7%) had received three or more prior chemotherapies.

At the visit cut-off date (November 30, 2015), 9 of 42 patients (21.4%) remained on treatment. Twenty-six of 42 patients (61.9%) discontinued because of disease progression (52.4%) or clinical decline (9.5%), 4 (9.5%) discontinued because of an AE, 2 (4.8%) discontinued because of increase in CA-125 level, and 1 (2.4%) discontinued upon investigator decision. Median treatment exposure was 7.4 months (range, 0.1–20.2).

Efficacy. Of 42 patients, 25 (59.5%) achieved an investigator-assessed, confirmed RECIST response and 35 (83.3%) achieved an investigator-assessed, RECIST/GCIG CA-125 response (Table 3). Activity was observed in patients with either a *BRCA1*

or *BRCA2* mutation, those with a PFI of 6 to 12 months or more than 12 months, as well as those who had received at least three prior chemotherapy regimens. Most patients (60.0%; 15/25) with a RECIST response achieved a response by the first disease assessment (approximately 6 weeks), and all but 2 of the responders achieved a response by the second disease assessment (approximately 12 weeks). The majority of patients (88.1%; 37/42) had a reduction in target lesion size (Fig. 1B). An example of a patient with visceral disease who had received two prior platinum-based regimens and achieved a PR to rucaparib at cycle 2 (51% decrease in sum of target lesions) is shown in Supplementary Fig. S4. Notably, the patient with clear cell ovarian cancer and the patient with endometrioid ovarian cancer each achieved a PR, as did many patients with serous ovarian cancer; thus the presence of a *BRCA* mutation appears to play a larger role than histology in determining response to rucaparib. The median duration of investigator-assessed confirmed response for patients in part 2A was 7.8 months (95% CI, 5.6–10.5). Nine of the 25 responders were censored at the visit cut-off date. Of these 9 patients, 5 were ongoing and 4 discontinued treatment for reasons other than disease progression (Fig. 1C). In a retrospective analysis, the confirmed ORR by independent radiology review was 52.4% (95% CI, 36.4–68.0).

Safety. Treatment-emergent AEs (all grades) were reported in all 42 patients (100.0%; Table 2), the most common of which were asthenia/fatigue, nausea, anemia, ALT/AST elevations, vomiting, constipation, and headache. Treatment-emergent




Figure 1. Waterfall plots for best overall change from baseline in target lesions in patients with advanced solid tumors (part 1, phase I dose escalation; $n = 40$; **A**) and patients with germline *BRCA1/2*-mutated high-grade ovarian cancer (part 2A, phase II expansion; $n = 40$; **B**) who had both baseline and postbaseline measurements. **C**, Duration of response for patients in part 2A. In **A**, patients with a *BRCA1* or *BRCA2* mutation detected by local testing are indicated with triangles or circles; for mutations detected in tumor tissue only (open triangles and circles), germline status was not determined.

AEs of elevations in blood creatinine were reported in 33.3% of patients (14/42) and were grade 1 or 2. Grade 3 or 4 treatment-emergent AEs were reported in 32 of 42 patients (76.2%); those reported in 10% or more of patients included asthenia/fatigue [grade 3, 26.2% (11/42); grade 4, none], anemia [grade 3, 31.0% (13/42); grade 4, 7.1% (3/42)], and elevated ALT/AST [grade 3,

14.3% (6/42); grade 4, none; Table 2]. Four of 42 patients (9.5%) discontinued treatment because of an AE, including abdominal cramps, constipation, dizziness, fatigue, hypercholesterolemia, nausea, shaking, urinary tract infection, and vomiting; 26 of 42 patients (61.9%) discontinued because of disease progression or clinical deterioration. There were three deaths that resulted from

Kristeleit et al.

Table 4. Single-dose and steady-state plasma pharmacokinetic parameters of rucaparib following once- or twice-daily continuous oral administration (part 1, phase I dose escalation)

Dosage	N	Day	Arithmetic mean C_{max} (CV%), ng/mL	Median T_{max} (range), h	Arithmetic mean $AUC_{0-\tau}$ (CV%), ng·h/mL	Arithmetic mean CL_{ss}/F (CV%), L/h	AR (CV%)	Arithmetic mean $t_{1/2}$ (CV%), h
40 mg QD	3	1	129 (28)	2.5 (1-4)	915 ^a	NR	NA	13.9 (57)
		15	138 (36)	4 (1-4.05)	1,810 (44)	26.7 (59)	1.68 ^a	25.7 (23)
80 mg QD	3	1	114 (41)	1.5 (1-2.5)	800 (27)	NR	NA	11.0 ^a
		15	175 (37)	2.5 (2.5-2.57)	1,740 (20)	47.5 (23)	2.33 (42)	19.5 ^a
160 mg QD	4	1	261 (51)	4.0 (4-6.05)	3,050 (51)	NR	NA	19.9 (21)
		15	288 (29) ^b	3.75 (2.5-4) ^b	4,110 (33) ^b	41.6 (29) ^b	1.84 (31) ^b	33.6 (12) ^b
300 mg QD	3	1	629 (37)	2.5 (1-4.08)	5,740 (38)	NR	NA	15.2 (72)
		15	693 (76)	2.53 (2.5-8)	9,610 (83)	46.7 (63)	1.60 (53)	29.8 ^a
500 mg QD	3	1	949 (52)	4 (4-4)	11,000 (61)	NR	NA	15.0 (32)
		15	1390 (23)	4 (4-4.17)	19,900 (41)	27.8 (35)	1.94 (17)	20.8 (38)
240 mg BID	3	1	219 (72)	6 (4.05-6)	2,800 ^c	NR	NA	NR ^h
		15	971 (49)	1.5 (1-4)	15,700 ^a	27.3 ^a	5.44 ^c	NR ^h
360 mg BID	8	1	666 (58)	3.23 (1.5-6)	4,860 (58) ^d	NR	NA	NR ^h
		15	1,300 (43) ^d	3.3 (0-6.33) ^d	9,430 ^a	40.4 ^a	4.08 ^a	NR ^h
480 mg BID	9	1	1,150 (57)	2.5 (1.5-4)	8,810 (63) ^e	NR	NA	NR ^h
		15	3,170 (69) ^e	1.51 (0-6) ^e	26,300 (73) ^d	26.2 (63) ^d	3.97 (38) ^f	NR ^h
600 mg BID	7	1	1,030 (61)	4 (2.42-10)	7,200 (66) ^g	NR	NA	NR ^h
		15	2,420 (45)	4 (2.53-10)	21,400 (61) ^g	58.6 (123) ^g	3.23 (66) ^g	NR ^h
840 mg BID	3	1	1,380 (69)	4 (2.5-8)	13,200 ^a	NR	NA	NR ^h
		15	3,030 (NR) ^a	4.04 (4-4.07) ^a	29,000 ^c	29 ^c	1.47 ^c	NR ^h

Abbreviations: AR, accumulation ratio based on AUC; $AUC_{0-\tau}$, area under the plasma concentration-time curve from 0 to the end of dosing interval ($\tau = 24$ hours for QD; $\tau = 12$ hours for BID; for BID dosing, concentration at 12 hours was calculated by extrapolation from last observed concentration in the same dosing interval); BID, twice daily; CV, coefficient of variation; NA, not available; NR, not reportable; QD, once daily.

^a $n = 2$.

^b $n = 3$.

^c $n = 1$.

^d $n = 6$.

^e $n = 8$.

^f $n = 5$.

^g $n = 4$.

^h $t_{1/2}$ is too long to allow for accurate estimate in BID dosing.

disease progression; no treatment-related deaths were reported during the study.


Among 42 patients, treatment-emergent AEs led to a dose reduction in 29 patients (69.0%) and treatment interruption in 27 patients (64.3%). Thirty-eight patients (90.5%) had at least one dose reduction or treatment delay because of a treatment-emergent AE. Grade 3 or 4 AEs were managed with treatment modification and/or supportive care. In most patients, myelosuppression was a cumulative effect that manifested after cycle 1 and was successfully treated with supportive care and/or dose interruption or modification. Transient elevations in ALT and/or AST, with no other evidence of liver dysfunction, occurred relatively early after initiation of treatment (middle of cycle 1 or start of cycle 2) and resolved or stabilized over time, including during continued rucaparib exposure (Fig. 2).

Discussion

In this phase I-II study, oral rucaparib had a manageable safety profile and favorable pharmacokinetic properties. During dose escalation, rucaparib was active in patients who had a germline *BRCA1/2* mutation, with responses observed in patients with ovarian (platinum-sensitive and platinum-resistant), breast, and pancreatic tumors. Part 2A data indicated that administration of rucaparib 600 mg twice daily led to robust responses in patients with platinum-sensitive, relapsed, high-grade, serous, endometrioid, and/or clear cell ovarian cancer associated with a germline or tumor *BRCA1/2* mutation.

This study was the first to fully evaluate daily, single-agent oral rucaparib in patients with an advanced solid tumor and to provide a comprehensive characterization of its safety and pharmacokinetic profile. Continuous dosing of oral rucaparib was associated with approximately dose-proportional rucaparib exposure in the tested dose ranges following once-daily and twice-daily administration, with moderate interpatient variability and a $t_{1/2}$ of approximately 17 hours independent of dose. In a small cohort of patients, a high-fat meal did not cause clinically meaningful changes in rucaparib pharmacokinetics, indicating that patients may take rucaparib with or without food. During the dose escalation phase of the study (part 1), no MTD was identified in patients treated with rucaparib doses up to 840 mg twice daily; however, delayed myelosuppression requiring dose modification was observed in some patients treated with rucaparib 600 mg twice daily. The 600 mg twice-daily dose was selected as the RP2D based on manageable safety and clinical activity, and was further characterized in the phase II portion.

Oral rucaparib 600 mg twice daily was tolerable, with a manageable safety profile that was consistent with its mechanism of action. Toxicities observed with rucaparib, such as myelosuppression, fatigue, and gastrointestinal disorders, are commonly observed with other PARP inhibitors (19, 23, 24, 37, 38). Myelosuppression, which generally occurs at a lower frequency with PARP inhibitors in relation to platinum-based chemotherapy, was generally observed after several cycles of rucaparib treatment and was successfully managed with supportive care and treatment modification (dose reduction and/or

**Figure 2.**

Baseline and on-treatment values for alanine aminotransferase (A), aspartate aminotransferase (B), and bilirubin (C) for patients in part 2A ($n = 42$). Dashed gray lines indicate the upper and lower limits of the normal range.

interruption). Other common low-grade AEs included fatigue and gastrointestinal side effects, such as nausea and vomiting. These AEs were successfully managed with supportive care and/or dose modification, as needed. Elevated serum creatinine was observed during rucaparib treatment. Elevations in creatinine have also been observed following the use of the PARP inhibitor olaparib (27). Elevations in creatinine may be attrib-

uted to the inhibition of the active tubular secretion of creatinine into the proximal tubule and subsequent apical efflux into the urine, as rucaparib has demonstrated potent inhibition of MATE1 and MATE2-K and moderate inhibition of OCT-2 *in vitro*. Inhibition of these transporters has also been demonstrated *in vitro* with the PARP inhibitor veliparib and other drugs (39, 40). Some AEs observed with rucaparib treatment,

Krissteleit et al.

such as elevations in ALT and AST, have not been previously associated with PARP inhibitors. The mechanism responsible for the transaminase elevations has not been identified; however, such elevations were transient and resolved or stabilized during treatment. Of the 98 patients treated in Study 10 (parts 1 and 2 combined), 87 patients discontinued treatment because of disease progression (62/98; 63.3%), clinical progression (14/98; 14.3%), treatment-emergent AE (5/98; 5.1%), or other reason (6/98; 6.1%). No treatment-related deaths were reported in either part 1 or part 2A.

The benefits of PARP inhibitors for treatment of germline *BRCA1/2*-mutated ovarian cancer are well established, with response rates in the range of 38% to 60% reported in patients with platinum-sensitive disease (16, 18, 19, 24, 41–43). In the 42 patients with platinum-sensitive, relapsed HGOC associated with a germline *BRCA1/2* mutation enrolled in part 2A of this study (600 mg twice daily), the investigator-assessed ORR was 59.5% by RECIST and 83.3% by RECIST/CA-125 criteria.

Part 2B of this study is currently assessing the efficacy of rucaparib in patients with relapsed HGOC associated with a germline or somatic *BRCA1/2* mutation who had received at least three prior chemotherapy regimens. Part 3 is ongoing and currently assessing the pharmacokinetic (including the effect of food) and safety profile of a higher dose tablet of rucaparib in patients with a relapsed solid tumor associated with a germline or somatic *BRCA1/2* mutation.

This study provides evidence of the antitumor activity of rucaparib in patients with germline *BRCA1/2*-mutated ovarian cancer. Results from this study and the ongoing phase II ARIEL2 study (NCT01891344) supported the accelerated approval of rucaparib (600 mg twice daily) by the FDA for the treatment of patients with advanced ovarian cancer associated with deleterious germline or somatic *BRCA* mutations who have received two or more chemotherapies. Additional preclinical data indicate that the antitumor activity of rucaparib extends beyond tumors with a *BRCA1/2* mutation to a broader group of tumors with HRD (32, 44, 45). For this reason, rucaparib is being developed for the treatment of tumors with HRD, including those with a *BRCA1* or *BRCA2* mutation (ClinicalTrials.gov identifiers: NCT00664781, NCT01074970, NCT01482715, NCT01891344, NCT01968213, NCT02042378, and NCT02505048). In addition to the ARIEL2 study, which is investigating rucaparib in the treatment setting, rucaparib is being evaluated in the maintenance setting in patients with relapsed HGOC in the phase III ARIEL3 study (NCT01968213). The ARIEL2 and ARIEL3 studies are enrolling patients with or without a germline or somatic *BRCA1/2* mutation to investigate the activity of rucaparib in a wider group of patients with HRD-associated ovarian cancer. The ARIEL clinical development program is prospectively testing a novel next-generation sequencing HRD assay and algorithm to predict which patients with ovarian cancer, including those whose tumors lack a *BRCA1* or *BRCA2* mutation, may benefit from rucaparib. Results from ARIEL2 part 1 indicate that some patients who have *BRCA1/2* wild-type tumors and have a high percentage of tumor genomic loss of heterozygosity respond to rucaparib

treatment (43). In ARIEL3, this novel HRD assay will be prospectively applied to the primary analysis of investigator-assessed progression-free survival by RECIST with the aim of validating the test to identify patients with HRD tumors who will be most likely to benefit from rucaparib.

Disclosure of Potential Conflicts of Interest

R. Kristeleit has been a consultant for Medivation, reports receiving speakers bureau honoraria from AstraZeneca, and is a consultant/advisory board member for Clovis Oncology. G.I. Shapiro reports receiving other commercial research support from Eli Lilly and Company. J. Balmaña reports receiving speakers bureau honoraria from AstraZeneca and is a consultant/advisory board member for Clovis Oncology and TESARO, Inc. Y. Drew reports receiving commercial research grants from Clovis Oncology and is a consultant/advisory board member for AstraZeneca and Clovis Oncology. L.-m. Chen reports receiving lecture fees from Clovis Oncology. H. Giordano, J. Borrow, and L. Rolfe hold ownership interest (including patents) in Clovis Oncology. J. Xiao has ownership interest in Clovis Oncology. R. Shapira-Frommer is a consultant/advisory board member for Clovis Oncology. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: R. Kristeleit, G.I. Shapiro, H.A. Burris, Y. Drew, T. Safra, H. Giordano, S. Goble, L. Rolfe

Development of methodology: R. Kristeleit, H.A. Burris, H. Giordano, S. Goble, J. Isaacson, L. Rolfe

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R. Kristeleit, G.I. Shapiro, H.A. Burris, A.M. Oza, P. LoRusso, M.R. Patel, S.M. Domchek, J. Balmaña, Y. Drew, L.-m. Chen, T. Safra, A. Montes, L. Maloney, J. Xiao, L. Rolfe, R. Shapira-Frommer

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R. Kristeleit, G.I. Shapiro, H.A. Burris, A.M. Oza, P. LoRusso, M.R. Patel, S.M. Domchek, L.-m. Chen, H. Giordano, L. Maloney, S. Goble, J. Isaacson, J. Xiao, L. Rolfe, R. Shapira-Frommer

Writing, review, and/or revision of the manuscript: R. Kristeleit, G.I. Shapiro, H.A. Burris, A.M. Oza, P. LoRusso, M.R. Patel, S.M. Domchek, J. Balmaña, Y. Drew, L.-m. Chen, T. Safra, A. Montes, H. Giordano, L. Maloney, S. Goble, J. Isaacson, J. Xiao, J. Borrow, R. Shapira-Frommer

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H.A. Burris, L.-m. Chen, L. Maloney, J. Borrow

Study supervision: R. Kristeleit, H.A. Burris, M.R. Patel, L.-m. Chen, H. Giordano, L. Maloney, L. Rolfe

Acknowledgments

The authors thank Mark Morgan, MD, for his thoughtful comments and discussion and Sara Jaw-Tsai for her assistance with the pharmacokinetic data. Writing and editorial assistance funded by Clovis Oncology, Inc., was provided by Tim Lohret, PhD; Nathan Yardley, PhD; and Shannon Davis of Ashfield Healthcare Communications (Middletown, Connecticut).

Grant Support

This study was funded by Clovis Oncology, Inc. R. Kristeleit and this study were supported by the UCL Experimental Cancer Medicine Centre and the NIHR UCLH Biomedical Research Centre and Clinical Research Facility.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 9, 2016; revised December 5, 2016; accepted February 28, 2017; published OnlineFirst March 6, 2017.

References

- Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. *Nat Rev Mol Cell Biol* 2006; 7:517–28.
- Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: from mechanistic understanding to cancer treatment. *DNA Repair* 2007;6:923–35.

3. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. *Nat Rev Cancer* 2008; 8:193–204.
4. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. *Mol Cell* 1999;4:511–8.
5. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. *Mol Cell* 2001;7: 263–72.
6. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 2002;108:171–82.
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913–7.
8. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–21.
9. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP)ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. *J Clin Oncol* 2008;26: 3785–90.
10. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. *Mol Oncol* 2011; 5:387–93.
11. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. *Cancer Discov* 2015;5:1137–54.
12. Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. *Nature* 2015;518:258–62.
13. Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzarini-Denchi E, Sfeir A. Mammalian polymerase [THGR] promotes alternative NHEJ and suppresses recombination. *Nature* 2015;518:254–7.
14. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshov JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. *Cancer Res* 2012;72:5588–99.
15. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–34.
16. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 2010;376: 245–51.
17. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 2010;376:235–44.
18. Kaye SB, Lubinski J, Matulonis U, Ang JE, Courley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. *J Clin Oncol* 2012; 30:372–9.
19. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncol* 2013;14:882–92.
20. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. *Clin Cancer Res* 2013; 19:5003–15.
21. Burgess M, Puhalla S. BRCA 1/2-mutation related and sporadic breast and ovarian cancers: more alike than different. *Front Oncol* 2014;4:19.
22. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, et al. Phase I/II study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. *J Natl Cancer Inst* 2014;106:dju089.
23. Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, et al. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. *Cancer Chemother Pharmacol* 2014;74: 257–65.
24. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol* 2015;33:244–50.
25. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. *J Clin Oncol* 2015;33:1397–406.
26. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. *Clin Cancer Res* 2015;21:1574–82.
27. AstraZeneca Pharmaceuticals. LYNPARZA (olaparib) capsules [prescribing information]; 2017. Available from: http://www.azpicentral.com/Lynparza/pi_lynparza.pdf#page=1.
28. Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. *Clin Cancer Res* 2015;21:4257–61.
29. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. *Mol Cancer Ther* 2007;6:945–56.
30. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. *Nat Biotechnol* 2012; 30:283–8.
31. Clovis Oncology, Inc. Rubraca (rucaparib) tablets [prescribing information]; 2016. Available from: <http://clovisoncology.com/files/rubraca-prescribing-info.pdf>.
32. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. *J Natl Cancer Inst* 2011;103:334–46.
33. Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley MS, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. *Br J Cancer* 2016;114:723–30.
34. National Cancer Institute. CTCAE [cited 2016 Nov 15]; 2016. Available from: <https://nciterns.nci.nih.gov/ncitbrowser/pages/vocabulary.jsf?dictionary=CTCAE&version=4.03>.
35. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
36. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCG). *Int J Gynecol Cancer* 2011; 21:419–23.
37. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382–92.
38. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol* 2015; 137:386–91.
39. Kikuchi R, Lao Y, Bow DA, Chiou WJ, Andracki ME, Carr RA, et al. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). *J Pharm Sci* 2013;102:4426–32.
40. Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. *Kidney Int* 2014;86:350–7.
41. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in

Kristeleit et al.

- BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 2010;28:2512-9.
42. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol* 2011;12:852-61.
43. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2017;18:75-87.
44. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. *Clin Cancer Res* 2010;16:2344-51.
45. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clin Cancer Res* 2014;20:764-75.

Clinical Cancer Research

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline *BRCA1/2*-Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, et al.

Clin Cancer Res 2017;23:4095-4106. Published OnlineFirst March 6, 2017.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-16-2796
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2017/03/03/1078-0432.CCR-16-2796.DC1

Cited articles	This article cites 42 articles, 13 of which you can access for free at: http://clincancerres.aacrjournals.org/content/23/15/4095.full#ref-list-1
Citing articles	This article has been cited by 10 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/23/15/4095.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/23/15/4095 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.